| Autor: |
Chaaban S; Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198-6450, USA., Sadikot RT; Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198-6450, USA.; VA Nebraska-Western Iowa Health Care System, Omaha, NE 68105, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Pathogens (Basel, Switzerland) [Pathogens] 2023 Mar 15; Vol. 12 (3). Date of Electronic Publication: 2023 Mar 15. |
| DOI: |
10.3390/pathogens12030464 |
| Abstrakt: |
There are about 200 different types of interstitial lung disease (ILD), and a crucial initial step in the assessment of a patient with suspected ILD is achieving an appropriate diagnosis. Some ILDs respond to immunosuppressive agents, while immunosuppression can be detrimental in others, hence treatment is based on the most confident diagnosis with consideration of a patient's risk factors. Immunosuppressive medications have the potential to result in substantial, and perhaps life-threatening, bacterial infections to a patient. However, data on the risk of bacterial infections from immunosuppressive treatment specifically in patients with interstitial lung disease is lacking. We hereby review the immunosuppressive treatments used in ILD patients excluding sarcoidosis, highlight their risk of bacterial infections, and discuss the potential mechanisms that contribute to the increased risk of infections. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
